This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n15http://linked.opendata.cz/resource/domain/vavai/projekt/
n17http://linked.opendata.cz/ontology/domain/vavai/
n11http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n5http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023736%3A_____%2F10%3A00008797%21RIV12-MZ0-00023736/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023736%3A_____%2F10%3A00008797%21RIV12-MZ0-00023736
rdf:type
skos:Concept n17:Vysledek
dcterms:description
Nuclear factor-kappaB (NF-kappaB) upregulates the transcription of proteins that promote cell survival, stimulate growth, induce angiogenesis and reduce susceptibility to apoptosis. NF-kappaB signaling pathway is constitutively activated in myelodysplastic syndrome (MDS), acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, lymphomas and in multiple myeloma (MM). The overexpression of NF-kappaB and its anti-apoptotic cytoprotective effect suggest that it might be a useful therapeutic target for the treatment of hematologic malignancies. Several drugs effective for the treatment of MM, including proteasome inhibitors, thalidomide, lenalidomide and arsenic trioxide, block NF-kappaB activation. New agents with NF-kappaB inhibitory ativity enhance the anti-MM effects of conventional chemotherapeutic agents and reduce different side-effects. These agents are also studied in the therapy of other hematologic malignancies. Nuclear factor-kappaB (NF-kappaB) upregulates the transcription of proteins that promote cell survival, stimulate growth, induce angiogenesis and reduce susceptibility to apoptosis. NF-kappaB signaling pathway is constitutively activated in myelodysplastic syndrome (MDS), acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, lymphomas and in multiple myeloma (MM). The overexpression of NF-kappaB and its anti-apoptotic cytoprotective effect suggest that it might be a useful therapeutic target for the treatment of hematologic malignancies. Several drugs effective for the treatment of MM, including proteasome inhibitors, thalidomide, lenalidomide and arsenic trioxide, block NF-kappaB activation. New agents with NF-kappaB inhibitory ativity enhance the anti-MM effects of conventional chemotherapeutic agents and reduce different side-effects. These agents are also studied in the therapy of other hematologic malignancies.
dcterms:title
Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies
skos:prefLabel
Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies Transcription factor NF-kappaB inhibitors as single therapeutics agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies
skos:notation
RIV/00023736:_____/10:00008797!RIV12-MZ0-00023736
n3:aktivita
n12:Z n12:P
n3:aktivity
P(LC06044), Z(MZ0UHKT2005)
n3:cisloPeriodika
3
n3:dodaniDat
n8:2012
n3:domaciTvurceVysledku
n16:7991401
n3:druhVysledku
n14:J
n3:duvernostUdaju
n13:S
n3:entitaPredkladatele
n5:predkladatel
n3:idSjednocenehoVysledku
293274
n3:idVysledku
RIV/00023736:_____/10:00008797
n3:jazykVysledku
n4:eng
n3:klicovaSlova
hematological malignancies; NF-kappaB; NF-kappaB inhibitors; proteasome inhibitors
n3:klicoveSlovo
n7:NF-kappaB%20inhibitors n7:NF-kappaB n7:proteasome%20inhibitors n7:hematological%20malignancies
n3:kodStatuVydavatele
AE - Stát Spojené arabské emiráty
n3:kontrolniKodProRIV
[BABB4FE9BF12]
n3:nazevZdroje
Current Molecular Pharmacology
n3:obor
n18:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
1
n3:projekt
n15:LC06044
n3:rokUplatneniVysledku
n8:2010
n3:svazekPeriodika
3
n3:tvurceVysledku
Fuchs, Ota
n3:zamer
n11:MZ0UHKT2005
s:issn
1874-4672
s:numberOfPages
25